Generic · Suppository
Hydromorphone 3 mg suppository price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for hydromorphone 3 mg suppository this week. The makers, package codes, recalls and label are below.
What people paid for hydromorphone 3 mg suppository
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Shortages
- Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)
- Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)
- Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)
- Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)
- Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)Limited Supply Available. Next Delivery and Estimated Recovery: December 2026
- Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)
- Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)Check wholesalers for inventory
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 189 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
2 companies sell hydromorphone 3 mg suppository under 2 package codes (NDCs).
| Maker | Package codes | Per unit |
|---|---|---|
| Bryant Ranch Prepack | 63629-2532-1 | - |
| Padagis US LLC | 0574-7224-06 | - |
All 2 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other hydromorphone strengths and forms
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 2 mg/mL, 1 mL cartridge | Not priced this week | |||
| 8 mg (24 hr) extended-release tablet | $5.71 | $171.43 / 30 tablets | ||
| 12 mg (24 hr) extended-release tablet | $10.58 | $317.48 / 30 tablets | ||
| 16 mg (24 hr) extended-release tablet | $12.38 | $371.41 / 30 tablets | ||
| 2 mg/mL injection | Not priced this week | |||
| 2 mg/mL, 1 mL injection | $2.74 | $68.51 / 25 mL | ||
| 10 mg/mL, 5 mL injection | $2.57 | $128.31 / 50 mL | ||
| 10 mg/mL, 50 mL injection | $2.57 | $128.31 / 50 mL | ||
| 1 mg/mL oral solution | $0.2341 | $110.71 / 473 mL | ||
| 2 mg tablet | $0.1708 | $5.12 / 30 tablets | ||
| 4 mg tablet | $0.2202 | $6.61 / 30 tablets | ||
| 8 mg tablet | $0.5490 | $16.47 / 30 tablets | ||
Official label & what changed
These highlights do not include all the information needed to use HYDROMORPHONE HYDROCHLORIDE INJECTION and HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF) safely and effectively.See full prescribing information for HYDROMORPHONE HYDROCHLORIDE INJECTION and HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF). HYDROMORPHONE HYDROCHLORIDE injection and HYDROMORPHONE HYDROCHLORIDE injection [high potency formulation (HPF)], for intravenous, intramuscular, or subcutaneous use, CIIInitial U.S. Approval: January
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION AND HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF)
Risk of Medication Errors
Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is a more concentrated solution of hydromorphone than Hydromorphone Hydrochloride Injection, and is for use in opioid-tolerant patients only. Do not confuse Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] with standard parenteral formulations of Hydromorphone Hydrochloride Injection or other opioids, as overdose and death could result [see Warnings and Precautions (5.1)].
Addiction, Abuse, and Misuse
Because the use of Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.2)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of
Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection [high potency formulation (HPF)], especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] are essential [see Warnings and Precautions (5.3)].
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.4), Drug Interactions
(7)].
Neonatal Opioid Withdrawal Syndrome (NOWS)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.5)].
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION AND HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF)
See full prescribing information for complete boxed warning.
•
Do not confuse Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] with standard parenteral formulations of Hydromorphone Hydrochloride Injection or other opioids, as overdose and death could result. (5.1)
•
Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.2)
•
Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection (HPF) are essential. (5.3)
•
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.4, 7)
•
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.5)
Recent major changes (as listed on the label)
Boxed Warning 12/2025
Indications and Usage (1) 12/2025
Dosage and Administration (2.6) 12/2025
Warnings and Precautions (5.2, 5.3, 5.4, 5.11, 5.13) 12/2025
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about hydromorphone 3 mg suppository
Who makes hydromorphone 3 mg suppository?
2 companies: Bryant Ranch Prepack, Padagis US LLC. See every package code.
Is hydromorphone in shortage?
Yes - 27 products are listed as short or being discontinued. Details.
Has hydromorphone been recalled?
189 recalls on record, 3 ongoing. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about hydromorphone 3 mg suppository
No comments yet. Questions, tips, what worked for you - start the conversation.